- Home
- CULP vs ATNM Comparison
CULP vs ATNM Comparison
Compare CULP & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CULP
- ATNM
- Stock Information
- Founded
- CULP 1972
- ATNM 2000
- Country
- CULP United States
- ATNM United States
- Employees
- CULP N/A
- ATNM N/A
- Industry
- CULP Textiles
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- CULP Consumer Discretionary
- ATNM Health Care
- Exchange
- CULP Nasdaq
- ATNM Nasdaq
- Market Cap
- CULP 54.5M
- ATNM 49.0M
- IPO Year
- CULP N/A
- ATNM N/A
- Fundamental
- Price
- CULP $4.09
- ATNM $1.76
- Analyst Decision
- CULP
- ATNM Strong Buy
- Analyst Count
- CULP 0
- ATNM 2
- Target Price
- CULP N/A
- ATNM $4.50
- AVG Volume (30 Days)
- CULP 19.8K
- ATNM 176.2K
- Earning Date
- CULP 09-03-2025
- ATNM 08-08-2025
- Dividend Yield
- CULP N/A
- ATNM N/A
- EPS Growth
- CULP N/A
- ATNM N/A
- EPS
- CULP N/A
- ATNM N/A
- Revenue
- CULP $213,237,000.00
- ATNM N/A
- Revenue This Year
- CULP $2.41
- ATNM N/A
- Revenue Next Year
- CULP $3.46
- ATNM N/A
- P/E Ratio
- CULP N/A
- ATNM N/A
- Revenue Growth
- CULP N/A
- ATNM N/A
- 52 Week Low
- CULP $3.42
- ATNM $1.03
- 52 Week High
- CULP $6.85
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- CULP 44.27
- ATNM 59.47
- Support Level
- CULP $3.75
- ATNM $1.60
- Resistance Level
- CULP $4.12
- ATNM $1.76
- Average True Range (ATR)
- CULP 0.14
- ATNM 0.11
- MACD
- CULP -0.02
- ATNM 0.01
- Stochastic Oscillator
- CULP 51.77
- ATNM 92.52
About CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.